Evidence map›Paper›PMID 34205831›Full record

ArticleCancers2021

Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing-A Prospective Feasibility Study.

Marina Berger, Andrea Thueringer, Doritt Franz, Nadia Dandachi, Emina Talakić, Georg Richtig, Erika Richtig, Peter Michael Rohrer, Lukas Koch, Ingrid Hildegard Wolf and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Marina BergerDepartment of Dermatology, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-2486-4634
Andrea ThueringerDiagnostic and Research Institute of Pathology, Medical University of Graz, 8010 Graz, Austria.
Doritt FranzDiagnostic and Research Institute of Pathology, Medical University of Graz, 8010 Graz, Austria.
Nadia DandachiDepartment of Internal Medicine, Division of Oncology, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0001-9093-0743
Emina TalakićDepartment of Radiology, Medical University of Graz, 8036 Graz, Austria.
Georg RichtigDepartment of Internal Medicine, Division of Oncology, Medical University of Graz, 8036 Graz, Austria.
Erika RichtigDepartment of Dermatology, Medical University of Graz, 8036 Graz, Austria.
Peter Michael RohrerDepartment of Dermatology, Medical University of Graz, 8036 Graz, Austria.
Lukas KochDepartment of Dermatology, Medical University of Graz, 8036 Graz, Austria.
Ingrid Hildegard WolfDepartment of Dermatology, Medical University of Graz, 8036 Graz, Austria.
Catharina KochDepartment of Dermatology, Medical University of Graz, 8036 Graz, Austria.
Barbara Margaretha RainerDepartment of Dermatology, Medical University of Graz, 8036 Graz, Austria.
Maximilian KoellerDepartment of Pathology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0001-9699-3390
Martin PichlerDepartment of Internal Medicine, Division of Oncology, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-8701-9462
Hanno GerritsmannMedical Affairs Oncology, Novartis Pharma GmbH, 1020 Vienna, Austria.
Karl KashoferDiagnostic and Research Institute of Pathology, Medical University of Graz, 8010 Graz, Austria.
Ariane AigelsreiterDiagnostic and Research Institute of Pathology, Medical University of Graz, 8010 Graz, Austria.
Medical University of Graz · ATMedical University of Vienna · ATNovartis (Austria) · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We prospectively performed a longitudinal analysis of circulating tumor DNA (ctDNA) from 149 plasma samples and CT scans in Stage III and IV metastatic melanoma patients (

Indexed as

circulating tumor DNAcustom panelsmetastatic melanomanext-generation sequencingtreatment monitoring

Identifiers

PMID34205831
PMCPMC8233754
OpenAlexW3173849848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.